Bitterman Robert J purchased $10K of PHIO
Bitterman Robert J (Chairman, Pres. & CEO) purchased 10,000 shares of Phio Pharmaceuticals Corp. (PHIO) at $0.99 on 2026-06-26.
How this was made
The 30-second read
Why it matters
The newest fact is the open-market purchase of 10,000 shares at $0.9900, which may modestly influence sentiment but does not change fundamentals in the text.
Market read
Traders may note the insider buy as a small positive sentiment datapoint, but there is no operational catalyst in the filing.
What to watch
The disclosed buy value is relatively small ($9,900), and the filing provides no accompanying corporate update (no trial results, guidance, or financing).
Background
This is an SEC Form 4 insider transaction for Phio Pharmaceuticals, filed by CEO/chairman Bitterman Robert J.
Ticker impact
Phio Pharmaceuticals CEO and chairman Bitterman Robert J bought 10,000 shares in an open-market transaction at $0.9900 on 2026-06-26.
Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless followed by operational or financial news.
Insider buys can support sentiment, but this filing is small in dollar terms ($9,900) and contains no new guidance, trial, or deal information.
Market effects
Minimal; this is a single-company insider transaction with no sector-wide regulatory or clinical signal.
None indicated.
None indicated.
Counterpoint
Insider buys can be routine liquidity or portfolio rebalancing, and the absence of a 10b5-1 plan does not guarantee a strong forward signal.
Key entities
- issuerPhio Pharmaceuticals Corp.
Subject of the Form 4 insider transaction disclosure.
- insiderBitterman Robert J
Chairman, President, and CEO who executed the open-market purchase.
